Literature DB >> 8324894

The severe combined immunodeficient (SCID) mouse as a model for the study of autoimmune diseases.

A O Vladutiu1.   

Abstract

There are no readily available in vivo models to study immune cells from humans with autoimmune diseases. SCID mice, which virtually lack both T and B lymphocytes and accept xenogeneic cells, have been used during the last 5 years to provide a milieu for lymphocytes isolated from individuals with various autoimmune diseases, or for lymphocytes from mice that have a systemic lupus erythematosus-like syndrome. Whilst human autoantibodies to organ antigens have been demonstrated in most SCID mice engrafted with human lymphocytes from the peripheral blood or the target organ, inflammation of the mouse target organ has not generally been observed. This review critically analyses experiments in this area reported so far. Some pitfalls of the SCID mouse model of human autoimmune diseases are mentioned, and future experiments to study mouse and human autoimmunity with this model are proposed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8324894      PMCID: PMC1554753          DOI: 10.1111/j.1365-2249.1993.tb06488.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  28 in total

1.  Occurrence of mature B (IgM+, B220+) and T (CD3+) lymphocytes in scid mice.

Authors:  A M Carroll; R R Hardy; M J Bosma
Journal:  J Immunol       Date:  1989-08-15       Impact factor: 5.422

2.  The differences of susceptibility of the target thyroid gland to autoimmune thyroiditis and of antigenicity of thyroid gland for induction of experimental autoimmune thyroiditis.

Authors:  I Okayasu
Journal:  Clin Immunol Immunopathol       Date:  1986-12

3.  Severe combined immunodeficient (SCID) mice: a model for investigating human thyroid autoantibody synthesis.

Authors:  L Macht; N Fukuma; K Leader; D Sarsero; C A Pegg; D I Phillips; P Yates; S M McLachlan; C Elson; B Rees Smith
Journal:  Clin Exp Immunol       Date:  1991-04       Impact factor: 4.330

4.  Autoantibody production by severe combined immunodeficient mice reconstituted with synovial cells from rheumatoid arthritis patients.

Authors:  H Tighe; G J Silverman; F Kozin; R Tucker; R Gulizia; C Peebles; M Lotz; G Rhodes; K Machold; D E Mosier
Journal:  Eur J Immunol       Date:  1990-08       Impact factor: 5.532

5.  Autoimmune murine thyroiditis relation to histocompatibility (H-2) type.

Authors:  A O Vladutiu; N R Rose
Journal:  Science       Date:  1971-12-10       Impact factor: 47.728

6.  Studies on organ specificity. V. Changes in the thyroid glands of rabbits following active immunization with rabbit thyroid extracts.

Authors:  N R ROSE; E WITEBSKY
Journal:  J Immunol       Date:  1956-06       Impact factor: 5.422

7.  Limited B cell repertoire in severe combined immunodeficient mice engrafted with peripheral blood mononuclear cells derived from immunodeficient or normal humans.

Authors:  A Saxon; E Macy; K Denis; M Tary-Lehmann; O Witte; J Braun
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

8.  Generation of biliary lesions after transfer of human lymphocytes into severe combined immunodeficient (SCID) mice.

Authors:  S M Krams; K Dorshkind; M E Gershwin
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

9.  Transfer of human systemic lupus erythematosus in severe combined immunodeficient (SCID) mice.

Authors:  M A Duchosal; P J McConahey; C A Robinson; F J Dixon
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

10.  Evidence of functional lymphocytes in some (leaky) scid mice.

Authors:  G C Bosma; M Fried; R P Custer; A Carroll; D M Gibson; M J Bosma
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

View more
  12 in total

1.  A human anti-dsDNA monoclonal antibody caused hyaline thrombi formation in kidneys of 'leaky' SCID mice.

Authors:  L J Mason; C T Ravirajan; D S Latchman; D A Isenberg
Journal:  Clin Exp Immunol       Date:  2001-10       Impact factor: 4.330

2.  Immunohistochemical and ultrastructural evidence for myelopoiesis in the scid/scid mouse thymus.

Authors:  M D Kendall; D P Lane; U Schumacher
Journal:  Histochem J       Date:  1999-10

3.  Amelioration of lupus manifestations by a peptide based on the complementarity determining region 1 of an autoantibody in severe combined immunodeficient (SCID) mice engrafted with peripheral blood lymphocytes of systemic lupus erythematosus (SLE) patients.

Authors:  N Mauermann; Z Sthoeger; H Zinger; E Mozes
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

4.  Lupus manifestations in severe combined immunodeficient (SCID) mice and in human/mouse radiation chimeras.

Authors:  Zev Sthoeger; Heidy Zinger; Benny Dekel; Fabian Arditi; Yair Reisner; Edna Mozes
Journal:  J Clin Immunol       Date:  2003-03       Impact factor: 8.317

5.  Human/BALB radiation chimera engrafted with splenocytes from patients with idiopathic thrombocytopenic purpura produce human platelet antibodies.

Authors:  B Dekel; H Marcus; B Shenkman; A Shimoni; Y Shechter; A Canaan; A Berrebi; D Varon; Y Reisner
Journal:  Immunology       Date:  1998-07       Impact factor: 7.397

6.  The in vivo production of specific human antibodies by vaccination of human-PBL-SCID mice.

Authors:  W Walker; G Gallagher
Journal:  Immunology       Date:  1994-10       Impact factor: 7.397

Review 7.  Humanized Mouse Models of Systemic Lupus Erythematosus: Opportunities and Challenges.

Authors:  Jiaxuan Chen; Shuzhen Liao; Huimin Zhou; Lawei Yang; Fengbiao Guo; Shuxian Chen; Aifen Li; Quanren Pan; Chen Yang; Hua-Feng Liu; Qingjun Pan
Journal:  Front Immunol       Date:  2022-01-18       Impact factor: 7.561

Review 8.  HIV-1 and drug abuse comorbidity: Lessons learned from the animal models of NeuroHIV.

Authors:  Susmita Sil; Annadurai Thangaraj; Ernest T Chivero; Fang Niu; Muthukumar Kannan; Ke Liao; Peter S Silverstein; Palsamy Periyasamy; Shilpa Buch
Journal:  Neurosci Lett       Date:  2021-03-29       Impact factor: 3.197

9.  Soluble TNF mediates the transition from pulmonary inflammation to fibrosis.

Authors:  Nikos Oikonomou; Vaggelis Harokopos; Jonathan Zalevsky; Christos Valavanis; Anastasia Kotanidou; David E Szymkowski; George Kollias; Vassilis Aidinis
Journal:  PLoS One       Date:  2006-12-27       Impact factor: 3.240

10.  Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma.

Authors:  J D Robertson; K Nagesh; S N Jowitt; M Dougal; H Anderson; K Mutton; M Zambon; J H Scarffe
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.